secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001104659-23-079822
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma secures $25M loan from Innoviva, appoints Dr. Deborah Birx as CEO
-------------------------------------------------------------------------------

- Enters $25M secured term loan with Innoviva Strategic Opportunities LLC at 14% interest, matures Jan 2025.
- Extends existing convertible credit agreement maturity to Jan 2025 via amendment.
- Terminates CEO Brian Varnum; appoints Dr. Deborah Birx, former White House Coronavirus Task Force coordinator, as CEO and director.
- Proceeds to advance phage candidates AP-PA02 (Pseudomonas) and AP-SA02 (Staph) and build out cGMP manufacturing facility.
- Resets 2023 annual meeting date from Aug 29 to Sep 14, 2023; record date unchanged at July 10, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer